Abstract CT103: Clinical Safety and Activity in a Phase I Trial of AG-221, a First in Class, Potent Inhibitor of the IDH2-mutant Protein, in Patients with IDH2 Mutant Positive Advanced Hematologic Malignancies
Cancer Research（2014）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined